(Reuters) - In February, Columbia said it was dropping development of the gel, Prochieve, after a late-stage trial failed to meet its goal of reducing the rate of preterm birth in women with a previous preterm birth earlier than 35 weeks gestation.
The effect on cervical length was not the primary focus of the trial, the company said.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment